Quantifying and Understanding the Signs and Symptoms of Fever

NCT ID: NCT01287143

Last Updated: 2017-10-06

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

TERMINATED

Total Enrollment

99 participants

Study Classification

OBSERVATIONAL

Study Start Date

2011-01-13

Study Completion Date

2017-08-09

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Background:

\- Fever is a common symptom of illness, but it can involve many signs (a signal that something is not right in the body that can be seen by others, such as vomiting) and symptoms (a signal that something is not right in the body that are felt only by the person, such as pain) that may differ depending on the type of illness involved. Researchers are interested in studying individuals who have a fever to examine how often these signs and symptoms are experienced by patients.

Objectives:

\- To identify and evaluate the signs and symptoms of fever and examine their frequency in individuals who have fever.

Eligibility:

\- Individuals at least 8 years of age who are admitted to the NIH Clinical Center and have a fever (body temperature of at least 38 degrees Celsius/100.4 degrees Fahrenheit).

Design:

* Participants will be screened upon admission to the NIH Clinical Center.
* Researchers will review the Clinical Center admission records.
* Participants will complete a 15- to 20-minute survey with questions about how they are feeling and what symptoms they have experienced before, during and after an episode of fever.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Background:

Fever is one of the most prevalent signs in hospitalized patients, signaling the activation of the immune system.

There is little empiric evidence related to symptoms or signs that accompany changes in body temperature.

Understanding the nature, timing and relationship of patient signs and symptoms of fever will provide insight into the febrile process and guide more informed treatment.

Objectives:

The protocol is divided into two phases:

Phase I

-To develop and implement a simple clinical tool for assessing and documenting patient-reported signs and symptoms of fever.

Phase II

-To describe the prevalence and relationship of signs and symptoms that accompanies a febrile state and related patterns of change over time.

Eligibility:

Phase I

* Adult and pediatric medical-surgical patients hospitalized at the Clinical Center admitted to 3NE (oncology/ transplant), 3NW (surgical oncology) and 1NW (pediatric).
* Age greater than or equal to 8 years old
* Understand and speak English

Phase II

* Inpatients admitted to the Clinical Research Center
* Age greater than or equal to 8 years old.

Design:

Phase I

-Descriptive study involving qualitative interviews and chart reviews from medical surgical inpatients. Two types of interviews with two different sets of patients will be conducted. The maximum number of research participants for this phase will be 65. The final sample size will be determined based on the point of saturation, defined as four consecutive interviews during which no new signs or symptoms associated with fever are identified. The second set of interviews will involve 20 to 30 new research participants, including at least 5 patients less than 18 years of age who will review a list of signs and symptoms of fever for comprehension and clarity to inform the final list and determine the terminology to be used in the FAST.

Study of the Febrile Assessment Tool (FAST)

-Test of the FAST in 120 patients. Before placing the FAST in the electronic record (Clinical Research Information System-CRIS) this new assessment tool will be used in approximately 120 patients during routine vital sign measurements. Patients admitted to the surgical oncology unit (3NW) will be consented and followed with collection of the FAST assessments

Education Implementation

* Inform nursing staff of the background, content and procedures for using the Febrile Assessment Tool (FAST)
* Educational interim will last 4 weeks

Phase II

* Approximately 2 months or at the discretion of the PI after FAST education
* Descriptive study involving chart review from unidentified inpatients. The sample size will be a maximum of 500.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Fever

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

OTHER

Study Time Perspective

PROSPECTIVE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

Adult and pediatric medical-surgical patients hospitalized in the Clinical Center, NIH admitted to 3NE (oncology/ transplant), 3NW (surgical oncology) and 1NW (pediatrics).

Oriented to person, time and place at time of interview

Active fever (body temperature greater than or equal to 38.0 Celsius), treated or untreated, within the last 12 hours.

Willingness to participate in a short interview (15-20 minutes) about their symptoms

Understands and speaks English

Age 8 years and older


Adult (18 years of age or greater) medical-surgical patients hospitalized at the Clinical Center and admitted to 3NW.

Oriented to person, time and place at time of admission

Willingness to be asked about their symptoms of fever during vital signs assessment

Understands and speaks English


Inpatients admitted to the Clinical Center

Age 8 years and older
Minimum Eligible Age

18 Years

Maximum Eligible Age

100 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

National Institutes of Health Clinical Center (CC)

NIH

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Nancy Ames, R.N.

Role: PRINCIPAL_INVESTIGATOR

National Institutes of Health Clinical Center (CC)

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

National Institutes of Health Clinical Center, 9000 Rockville Pike

Bethesda, Maryland, United States

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States

References

Explore related publications, articles, or registry entries linked to this study.

Laupland KB. Fever in the critically ill medical patient. Crit Care Med. 2009 Jul;37(7 Suppl):S273-8. doi: 10.1097/CCM.0b013e3181aa6117.

Reference Type BACKGROUND
PMID: 19535958 (View on PubMed)

Chesnutt BK, Zamora MR, Kleinpell RM. Blood cultures for febrile patients in the acute care setting: too quick on the draw? J Am Acad Nurse Pract. 2008 Nov;20(11):539-46. doi: 10.1111/j.1745-7599.2008.00356.x.

Reference Type BACKGROUND
PMID: 19128337 (View on PubMed)

Bor DH, Makadon HJ, Friedland G, Dasse P, Komaroff AL, Aronson MD. Fever in hospitalized medical patients: characteristics and significance. J Gen Intern Med. 1988 Mar-Apr;3(2):119-25. doi: 10.1007/BF02596115.

Reference Type BACKGROUND
PMID: 3357068 (View on PubMed)

Ames NJ, Powers JH, Ranucci A, Gartrell K, Yang L, VanRaden M, Leidy NK, Wallen GR. A systematic approach for studying the signs and symptoms of fever in adult patients: the fever assessment tool (FAST). Health Qual Life Outcomes. 2017 Apr 27;15(1):84. doi: 10.1186/s12955-017-0644-6.

Reference Type DERIVED
PMID: 28449675 (View on PubMed)

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

11-CC-0083

Identifier Type: -

Identifier Source: secondary_id

110083

Identifier Type: -

Identifier Source: org_study_id